Clinical TrialsThe registrational Phase 2/3 trial of darovasertib and crizotinib in first-line metastatic uveal melanoma is enrolling ahead of schedule with potential to accelerate further with the addition of ex-US sites.
Financial PerformanceIDYA reported cash, equivalents, and marketable securities of $1.2 billion, providing a strong financial position.
Pipeline DevelopmentThe company is initiating multiple clinical dose expansions across its pipeline, suggesting a robust development strategy and potential for growth.